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Abstract Distal symmetric polyneuropathy (DSPN), the
most common form of diabetic neuropathy, has a complex
pathophysiology and can be a major source of physical and
psychologic disability. Themanagement of DSPN can be frus-
trating for both patient and physician. This article provides a
general overview of typical patient pathways in DSPN, and
highlights variations in diagnosis, management, and referral
patterns among different providers. DSPN is managed in sev-
eral settings by primary care physicians (PCPs), specialists,
and nurse practitioners. The initial clinical management of
the patient is often dependent on the presenting complaint,
the referral pattern of the provider, level of comfort of the
PCP in managing diabetic complications, and geographic ac-
cess to specialists. The primary treatment of DSPN focuses
mainly on glycemic control and adjustment of modifiable risk
factors, but other causes of neuropathy should also be inves-
tigated. Several pharmacologic agents are recommended by
treatment guidelines, and as DSPN typically exists with co-
morbid conditions, a multimodal therapeutic approach should
be considered. Barriers to effective management include fail-
ure to recognize DSPN, and misdiagnosis. Patient education
also remains important. Referral patterns vary widely accord-
ing to geographic location, access to services, provider pref-
erences, and comfort in managing complex aspects of the
disease. The variability in patient pathways affects patient
education, satisfaction, and outcomes. Standardized screening
tools, a multidisciplinary team approach, and treatment algo-
rithms for diabetic neuropathy should improve future care. To
improve patient outcomes, DSPN needs to be diagnosed soon-
er and interventions made before significant nerve damage
occurs.
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Introduction
Peripheral neuropathy affects 26 % to 47 % of people with
diabetes in the USA [1]. The most common form of diabetic
neuropathy is distal symmetric polyneuropathy (DSPN), oc-
curring in up to 50 % of patients with neuropathy. The patho-
physiology of DSPN is complex and its management can be
frustrating for both the patient and the physician. DSPN can be
a major source of disability, both physically and psychologi-
cally, and is an independent risk factor for depressive symp-
toms [2]. High pain levels are associated with poor sleep,
functioning, and productivity [3]. Direct and indirect costs,
including prescription medications and office visits, are also
significantly higher among patients with greater pain severity
[3].
The estimated annual cost of diabetic neuropathy and its
complications in the USA in 2003 was between $4.6 and
$13.7 billion [4]. Although diabetic neuropathy is often
thought of as an adult disease, neuropathy has been reported
in 11 % of youths with type 1 diabetes, and may occur sooner
after diagnosis in children with type 2 diabetes [5, 6]. This
review assesses typical patient pathways in DSPN and
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identifies variations in diagnosis, management, and referral
patterns among different providers.
Materials and Methods
Literature searches were carried out from the beginning of
2010 to June 2014 to identify published evidence on DSPN
and its management. PubMed was searched using the terms
‘(diabetic OR diabetes) AND (neuropathy OR pain)’ while
congresses of the European Association for the Study of Dia-
betes, American Diabetes Association, and International Dia-
betes Federation were searched using ‘neuropathy’, ‘pain’,
‘PDN’, and ‘DSPN’. All abstract titles were assessed for pa-
pers of relevance.
Types of Neuropathy
There are typical and atypical forms of DSPN [7, 8]. The
Toronto Consensus Panel on Diabetic Neuropathy defined
typical DSPN as a “chronic, symmetrical, length dependent
sensorimotor polyneuropathy” [9]. Atypical DSPN has a
monophasic or fluctuating course and may have asymmetric
or proximal symptoms, as well as motor involvement. Acute
painful DSPN has been characterized as an additional subtype
that presents predominantly with pain, particularly sharp, stab-
bing, and electric-shock sensations in the distal extremities
that may include nocturnal exacerbations [10]. Such painful
small-fiber neuropathy, with minimal objective neurologic
signs, may occur in prediabetes [11]. Other atypical forms of
neuropathy that occur in diabetes include focal and multifocal
neuropathies, such as mononeuropathies, cranial neuropa-
thies, plexopathies, radiculopathy, mononeuritis multiplex,
amyotrophy, predominantly small-fiber neuropathy, and auto-
nomic neuropathy. Chronic inflammatory demyelinating neu-
ropathy is also more common in diabetic than in non-diabetic
patients [12].
Symptoms and Clinical Features
The most common symptoms of DSPN are length dependent,
usually affecting the feet first and progressing proximally.
Symptoms are predominantly sensory and can be classified
as “positive” (tingling, burning, and other abnormal sensa-
tions) or “negative” (sensory loss, weakness, numbness, and
unsteady gait). Painful DSPN is often described as burning or
electric and tends to occur more often at night. Motor symp-
toms are less common but can occur later in the disease
course. Distal deep-tendon reflexes are typically reduced or
absent.
The most serious complications of DSPN include foot ul-
cers, Charcot foot abnormalities, injuries, and ultimately,
lower-extremity amputation, especially when concomitant
peripheral vascular disease causes foot ischemia. Degradation
of sensory function leading to imbalance and unsteadiness in
gait [13] with loss of proprioception results in increased like-
lihood of a fall [14]. Decreased sensation of the distal extrem-
ities makes small injuries and ulcers common, and more than
2 % of patients with diabetes develop new foot ulcers each
year [15]. The lifetime risk that a patient with diabetes will
acquire a foot lesion, including an ulcer or gangrene, is esti-
mated to be approximately 15 % to 25 % [16]. The chronic
nature of DSPN can lead to anxiety, depression,
catastrophizing behavior, an inability to accept chronic pain,
and sleep disturbances [17].
Risk Factors for DSPN
The most important risk factor for developing DSPN in
type 1 diabetes is poor glycemic control. In the Diabe-
tes Control and Complications Trial, intensive therapy
reduced development of clinical neuropathy by 64 %
compared with standard glucose control over 5 years
[18]. In the Epidemiology of Diabetes Interventions
and Complications follow-up study, the benefits of in-
tensive insulin treatment persisted for 14 years, despite
similar glycemic control between the groups following
study completion [19, 20••]. The EURODIAB IDDM
Complications Study found additional correlations be-
tween neuropathy and duration of type 1 diabetes, qual-
ity of metabolic control, age, height, cigarette smoking,
high-density lipoprotein cholesterol, proliferative diabet-
ic retinopathy, and cardiovascular disease [21].
Risk factors for DSPN in type 2 diabetes are similar
to the risks for vascular disease, such as smoking, obe-
sity, hyperlipidemia, age, and waist circumference.
Many of these risk factors are modifiable, highlighting
the importance of patient self-motivation and the poten-
tial influence of physician counseling in determining
disease progression. Among prediabetic patients, in-
creased fasting glucose and impaired glucose tolerance
are associated with a high risk of clinical DSPN, com-
parable with that of diabetic patients [22, 23], highlight-
ing the need for early therapeutic intervention. In pa-
tients with neuropathy associated with impaired glucose
tolerance, partial cutaneous re-innervation is possible
through improvements to diet and exercise after
counseling [24]. The United Kingdom Prospective Dia-
betes Study found a reduced risk of neuropathy with
intensive treatment compared with standard glycemic
control [25]. This reduced risk must be weighed against
the potential risk of overly aggressive glycemic control,
which may be associated with acute painful DSPN [26]
and increased cardiovascular risk and sudden death re-
lated to autonomic dysfunction [27–29].
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Pathophysiology
The pathophysiology of DSPN is not fully understood and is
likely multifactorial. Nerve biopsy from patients with painful
neuropathy indicates that there is degeneration of myelinated
and unmyelinated fibers [30, 31]. Metabolic derangements
have been implicated, such as oxidative and nitrosative stress,
accumulation of glycation end products, impaired calcium
homeostasis, and mitochondrial dysfunction [32–34], and in-
creased activity through the polyol pathway [35]. Impaired
insulin signaling may directly injure the dorsal root ganglia
and play a role in the pathogenesis [36]. The mechanisms
involved in metabolic syndrome may contribute to a self-
perpetuating cycle of oxidative and nitrosative stress, inflam-
matory signals, and disruption of normal cellular function
[37•, 38•]. Peripheral lesions may also have central effects,
particularly through central sensitization of nociceptive neu-
rons [39].
Diagnosis
Diagnosis of DSPN is primarily clinical and involves a thor-
ough history and physical examination with a focus on car-
diovascular and neurologic tests, and a detailed assessment of
the feet [40]. Early diagnosis of DSPN is imperative in
preventing irreversible damage; however, 50 % of patients
may be asymptomatic. A 1-g Semmes–Weinstein monofila-
ment is useful for detecting changes in sensitivity [41], and a
10-g monofilament is useful for predicting ulcer risk. A small
decrease in the duration of a vibratory stimulus sensation,
assessed with a 128-Hz tuning fork, is an early indicator of
neuropathy. A more quantitative vibration assessment is avail-
able using the Rydel–Seifer tuning fork. The hallux, as op-
posed to the fifth metatarsal head, is a more sensitive indicator
of neuropathy in patients with diabetes [42]. A careful exam-
ination of the foot should include a check for peripheral
pulses, to assess for peripheral vascular disease, and a visual
check for ulcers. As painful diabetic peripheral neuropathy
(pDPN) is usually symmetrical, patients with asymmetrical
symptoms or signs should be carefully assessed for other eti-
ologies of their symptomatology [9].
Nerve conduction studies (NCS) often form part of the
evaluation of DSPN, especially in atypical cases with
superimposed nerve entrapment or inflammatory demyelinat-
ing neuropathy and in patients with minimal or no objective
neurologic signs. While NCS are helpful in diagnosing pa-
tients with large-fiber neuropathy, they have limited utility in
diagnosing small-fiber neuropathy. Small-fiber function may
be assessed by skin biopsy and quantitation of intra-epidermal
nerve fiber density, particularly when results of NCS are nor-
mal. Skin biopsy is a minimally invasive procedure [43–46].
Decreased intra-epidermal nerve fiber density is indicative of
small-fiber neuropathy. Further imaging, such as computed
tomography or magnetic resonance imaging, is usually not
necessary unless there is clinical suspicion for nerve entrap-
ment or disc pathology.
As DSPN is a diagnosis of exclusion, other etiologies of
polyneuropathy should also be assessed: alcohol use; vitamin
B12 levels; vasculitis; serum protein electrophoresis and
immunofixation; infections (e.g., Lyme disease, HIV); and
cancer and related paraneoplastic syndromes [47]. For exam-
ple, patients with vitamin B12 deficiency have impaired sen-
sory and motor peripheral nerve function [48]. Notably pa-
tients may have functional consequences of vitamin B12 de-
ficiency even with levels in the “low normal” range, and
should receive supplementation with methylcobalamin [48].
Metformin may contribute to vitamin deficiency [49].
The Toronto Consensus Panel on Diabetic Neuropathy de-
fined specific diagnostic guidelines that estimate the severity
of DSPN based onNCS and various signs and symptoms [50].
Additionally, questionnaires are frequently used to identify
and quantify neuropathy including the Michigan Neuropathy
Screening Instrument [51], the McGill Pain Questionnaire
[52], the Neuropathic Pain Questionnaire [53], the Brief Pain
Inventory [54], the Neuropathic Pain Symptom Inventory
[55], the Norfolk Quality of Life Questionnaire-Diabetic Neu-
ropathy Questionnaire [56], and the Neuropathy and Foot
Ulcer-specific Quality of Life Instrument [57]. Standardized
screening tools provide a good clinical record for post-
treatment follow-up, are simple to use, and are easily admin-
istered by a physician assistant, nurse practitioner, or self-
completed by the patient before the office visit [58].
Treatment
The focus of DSPN management is disease modification and
symptomatic relief; no treatment completely prevents or re-
verses disease progression. Pancreas transplants [59], diet and
exercise [24], and topiramate [60] have all been shown to
induce small-fiber regeneration. Rational glycemic control is
the primary approach to manage symptoms and prevent fur-
ther damage, including falls and foot ulcers. Most clinical
trials have studied therapies for symptomatic pain relief. Al-
though various treatment approaches are recommended by
diabetic and national societies, this review focuses on phar-
macologic agents for symptomatic treatment. Duloxetine,
pregabalin, and tapentadol are Food and Drug Administration
(FDA)-approved medications for DSPN, althoughmany other
agents have been studied and are frequently used. To achieve
an optimal therapeutic outcome, it is important to identify and
treat any comorbid conditions. Some treatments may improve
pain and sleep by direct and indirect pathways. Many treat-
ments for DSPN require careful dose titration every 2–4weeks
based on efficacy and safety. Combinations may also be use-
ful, although consideration of potential drug–drug interactions
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is important, and combining first-line agents is not backed by
trial evidence [61•].
Various organizations, professional societies, and expert
panels have produced guidelines for the treatment of neuro-
pathic pain including DSPN, such as the Toronto Consensus
Panel on Diabetic Neuropathy [61•], the Neuropathic Pain
Special Interest Group (NeuPSIG) [62], the European Feder-
ation of Neurological Societies Task Force [63], the National
Institute for Health and Care Excellence (NICE) [64], the
American Association of Neurology (AAN) in collaboration
with the American Association of Neuromuscular and
Electrodiagnostic Medicine and the American Academy of
Physical Medicine and Rehabilitation [65], the Working
Group on the Diabetic Foot from the French-Speaking Society
of Diabetology [66], and the American Association of Clinical
Endocrinologists [67]. Several of these were compared in a
review by Spallone [68]; guidelines generally recommend
considering tricyclic antidepressants (TCAs), serotonin/
norepinephrine-reuptake inhibitors (SNRIs), and alpha-2-
delta ligands as first-line agents. Many guidelines also recom-
mend duloxetine as a first-line option.
Tricyclic Antidepressants
TCAs are commonly used agents for DSPN and their analge-
sic effect is likely to be mediated through a different pathway
from their antidepressant effect. Anticholinergic and cardiac
side effects are the biggest limitation to their use. Imipramine
and desipramine have a lower side-effect burden than amitrip-
tyline. The NeuPSIG guideline recommends TCAs as first-
line agents, although they urge caution when using them in
patients with ischemic cardiac disease or ventricular conduc-
tion abnormalities, suggesting a screening electrocardiogram
in patients aged ≥40 years and limiting doses to <100 mg/day
[69]. The NICE guideline focuses on pharmacologic recom-
mendations in the non-specialist setting and also includes
amitriptyline among their list of first-line agents [64]. The
clinical characteristics of these TCAs are summarized in
Table 1.
Serotonin/Norepinephrine-Reuptake Inhibitors
SNRIs, such as duloxetine and venlafaxine, regulate descend-
ing inhibitory pain pathways by inhibiting the reuptake of
serotonin and norepinephrine. In several clinical trials,
duloxetine has been shown to be efficacious for up to a year
[71]. The most common adverse effects of duloxetine include
nausea, whereas for venlafaxine they are gastrointestinal dis-
turbances. The NeuPSIG guideline recommends SNRIs as
first-line agents. They suggest caution in patients with cardiac
disease and advise a tapering schedule upon discontinuation
of the drug to prevent withdrawal [69]. The NICE guideline
recommends duloxetine as a first-line option; however,
venlafaxine is not recommended [64]. The AAN guideline
concludes that existing data are insufficient to recommend
amitriptyline, venlafaxine, or duloxetine over one another
[65]. The clinical characteristics of these SNRIs are summa-
rized in Table 2.
Anticonvulsants
Anticonvulsants have a long history in the treatment of neu-
ropathic pain. However, studies are sparse and results are in-
consistent. Carbamazepine, oxcarbazepine, and lamotrigine
block sodium channels and reduce neuronal excitability in
the peripheral and central nervous system. Carbamazepine
was one of the first antiepileptic drugs studied and had some
success in reducing pain in several small studies [72, 73]. The
most common side effects include dizziness, ataxia, sedation,
hyponatremia, blurred vision, and confusion in the elderly.
Some studies of lamotrigine report significant relief of
pDPN [74, 75], while others have failed to show any signifi-
cant benefit either as monotherapy [76] or as an adjunctive
treatment [77]. The most concerning, albeit uncommon, side
effect of lamotrigine is Stevens–Johnson syndrome, whereas
more common side effects include sedation, dizziness, and
ataxia.
The AAN guidelines conclude that sodium valproate
should be considered for the treatment of peripheral diabetic
neuropathy, whereas lamotrigine, oxcarbazepine, and
lacosamide should probably not be considered [65]. They also
conclude that there is insufficient evidence to support or refute
the use of topiramate. However, some evidence suggests that
topiramate can induce skin intra-epidermal nerve fiber regen-
eration and enhance neurovascular function [60].
Pregabalin and gabapentin are active at the alpha-2-
delta subunit of calcium channels; they decrease calcium
influx, thereby decreasing central sensitization [63, 70].
As they are eliminated through the kidney and not the
liver, the risk of drug–drug interactions is minimized.
Both medications require titration schedules, and side
effects include somnolence, dizziness, weight gain,
headache, dry mouth, and peripheral edema. Pregabalin
is the only medication that was given a level A recom-
mendation by the AAN guidelines [65]; gabapentin was
given a level B recommendation. Pregabalin and
gabapentin are also both recommended as initial treat-
ments for neuropathic pain in the NICE guidelines [64].
Improvements in patient function and quality of life in
response to pregabalin treatment are correlated with the
extent of pain relief [78]. However, rather than being
mediated solely through pain relief, these improvements
may also result from a combined effect on pain and
sleep disturbance and a direct effect on patient function.
The clinical characteristics of these anticonvulsants are
summarized in Table 3.
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Opioids
Chronic opioid use can lead to tolerance, dependence, consti-
pation, and rebound headaches. Tramadol has a low affinity
for μ-receptors and is a weak inhibitor of norepinephrine and
serotonin reuptake, and moderately relieves DSPN-associated
pain [79, 80]. Its side-effect profile includes constipation, se-
dation, and nausea. Tramadol has a lower potential for abuse
than many opioids, although it can also lower the seizure
threshold. Tapentadol, an FDA-approved agent for painful
DSPN, combines a dual mechanism of action in a single for-
mulation by combining an opioid agonist and a norepineph-
rine antagonist, which provides effective analgesia in patients
with DSPN [81–83].
The NeuPSIG guidelines suggest opioids should be re-
served for patients who do not respond to first-line medica-
tions, although they are recommended for acute neuropathic
pain, neuropathic pain due to cancer, episodic exacerbations
of severe neuropathic pain, and if necessary when titrating one
of the first-line agents [69]. The AAN guidelines suggest that
morphine sulfate, tramadol, and oxycodone controlled-release
are probably effective in lessening the pain of DSPN [65]. An
ultra-rapid acting fentanyl effervescent buccal tablet provides
rapid relief of breakthrough pain in patients with diabetic and
other forms of neuropathic pain [84].
Several studies indicate that rational combination therapy
improves efficacy versus monotherapy without significantly
increasing adverse effects [85–88]. For example, gabapentin
plus long-acting morphine sulfate appears to be superior to
either drug alone [87]. Prolonged-release oxycodone appears
to enhance the analgesic effects of gabapentin [86], although
low-dose oxycodone does not appear to improve analgesia
with pregabalin [88]. Tramadol plus acetaminophen appears
to provide comparable pain relief to gabapentin alone [85].
The clinical characteristics of these opioids are summarized
in Table 4.
Cannabinoids
Smoked cannabis provides pain relief in HIV-associated neu-
ropathy [89, 90]. However, cannabis oromucosal spray
(Sativex®) was not effective in a small study of patients with
painful polyneuropathy [91]. Side effects include headache,
dizziness, somnolence, dry mouth, constipation, and diarrhea.
Regulatory and legal obstacles further complicate the use of
cannabinoids for neuropathic pain. The clinical characteristics
of cannabis are summarized in Table 5.
Thioctic Acid
The antioxidant alpha-lipoic acid (thioctic acid) prevents pro-
gression of neuropathic impairments and improves neuropath-
ic sensory symptoms including pain [92–94]. Although not all
trials were conclusive and some were of poor methodologic
quality, meta-analyses demonstrate that intravenous alpha-
lipoic acid treatment is associated with significant short-term
pain relief and improvements in nerve conduction [92, 95].
Topical Agents
Capsaicin
Capsaicin is a transient receptor potential vanilloid type 1
(TRPV1) agonist. Capsaicin creams (0.025–0.075 %) de-
crease pain in DSPN [96, 97]. The NICE guidelines recom-
mend considering the use of capsaicin cream for patients with
localized neuropathic pain who wish to avoid or cannot toler-
ate oral treatments [64]. The AAN recommends considering
capsaicin for the treatment of pDPN (level B recommenda-
tion) [69].
A high-concentration 8% capsaicin patch, administered for
60 minutes by a healthcare professional, provides at least
12 weeks of pain relief in controlled studies of post-herpetic
neuralgia (PHN) [98, 99] and HIV-associated DSPN [100]. A
meta-analysis of six studies of patients with PHN or painful
HIV-associated DSPN confirmed that the high-concentration
8 % capsaicin patch provides significant improvements in
pain. The most commonly reported side effects were erythe-
ma, burning, or pain localized to the application site [101].
Repeated applications for up to 12 months in patients with
painful HIV-associated DSPN provide continued pain relief
Table 5 Summary of cannabis as a potential treatment option for diabetic peripheral neuropathy [63–65, 69, 70]




• Smoked cannabis relieves
HIV-associated neuropathy
• Not FDA-approved for pDPN
• Side effects include headache, dizziness, somnolence,
dry mouth, constipation, and diarrhea
• Cannabis spray showed no effect on painful polyneuropathy
• Medicolegal and regulatory hurdles
• Social stigma
FDA Food and Drug Administration, HIV human immunodeficiency virus, pDPN painful diabetic peripheral neuropathy
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with reproducible safety and tolerability [102]. The high-
concentration 8 % capsaicin patch is FDA approved for
PHN, and is approved in the European Union for all forms
of peripheral neuropathic pain in patients without diabetes.
Two controlled trials of the high-concentration 8 % capsaicin
patch in pDPN, NCT01533428 and NCT01478607, are com-
pleted, with results from the former showing significantly
greater reductions in average daily pain scores for a single
30-minute 8 % capsaicin patch application, maintained for
up to 12 weeks, compared with application of a placebo patch
(p=0.018), and results from the latter trial expected by the end
of 2015 [103, 104]. The clinical characteristics of capsaicin
are summarized in Table 6.
Lidocaine Patches
Lidocaine (5 %) medicated patches are approved by the FDA
for PHN. Lidocaine blocks sodium channels, so decreasing
ectopic discharges. Up to four lidocaine patches may be
applied per day. A comparative study indicated that lido-
caine (5 %) patches are as effective as pregabalin in reduc-
ing neuropathic pain and are well tolerated [105]. Adverse
effects include local skin reactions. The AAN recommends
that the patch may be considered for the treatment of dia-
betic neuropathy, giving it a level C recommendation. The
clinical characteristics of lidocaine are summarized in
Table 6.
Who Manages DSPN?
There is considerable variability in the role of the healthcare
provider who initially diagnoses and ultimately manages
DSPN. It can depend on the patient’s presenting symptom or
primary complaint, the referral pattern of the primary care
physician (PCP), and the patient’s geographic location and
access to specialists. As neuropathic symptoms may be the
initial complaint of patients with diabetes, they may first pres-
ent to neurologists, pain specialists, or podiatrists. These spe-
cialists must, therefore, recognize DSPN as an initial present-
ing symptom of diabetes. If the patient is not known to have
diabetes, blood screening should include HbA1c levels and an
oral glucose tolerance test. As the mainstay of DSPN therapy
is glycemic control, general diabetes management should re-
main within the realm of PCPs, endocrinologists, or diabetes
specialists. One benefit of the PCP managing patients with
DSPN is that they can also manage the other systemic com-
plications of diabetes beyond neuropathy.
Most PCPs try to manage the complications of diabetes
including DSPN until they face certain challenges. The 2013
NICE guidelines recommend referral to a specialist pain ser-
vice or a condition-specific specialist, such as a neurologist,
diabetologist, or oncologist, at any stage if the patient experi-
ences any of the following: severe pain; pain that significantly
affects their lifestyle, daily activities, and participation; or de-
terioration of their underlying health condition (Fig. 1) [106].
In a survey of PCPs and diabetologists, the majority of
PCPs did not routinely refer their patients with diabetes to
specialty diabetes care [107]. Two-thirds of PCPs reported
referring less than a quarter of their patients with diabetes to
specialists; reasons for referral included complications with
insulin therapy and use of advanced treatment strategies. PCPs
were unclear about who was responsible for diabetes manage-
ment after a specialty referral. Over three-quarters of special-
ists thought that less than half of PCP practices managed pa-
tients with diabetes effectively, through their care or referral to
specialists. Reasons were lack of time (73 %), lack of perspec-
tive on what to treat and when to refer (69 %), and lack of
experience or confidence in designing treatment algorithms
(68 %) [107]. The limited number of specialists in rural areas
may be a barrier to accessing specialty services. Telemedicine
1. Person with neuropathic pain presents in a non-specialist setting
2. Key principles of care
Agree a treatment plan:
    –  Take into account the concerns and expectations of the patient
    –  Discuss all aspects of the patient’s pain, its impact on their daily life, and the 
        potential benefits and risks of all types of available treatment 
    –  Take into account any comorbidities and concurrent medications, e.g.,:
             Sleep, anxiety, and depression may affect the choice of pharmacologic treatment
             Cardiovascular status of patient must be known before prescription of tricyclic
             antidepressants
   Consider referring the patient to a specialist pain and/or condition-specific 
   service at any stage
   Continue existing treatments for patients whose neuropathic pain is already 
   effectively managed
   Take overlap with old treatments into account when introducing a new 
   treatment
   Carry out an early clinical review of dosage titration, tolerability, and adverse 
   events after starting/changing a treatment
   Carry out regular clinical reviews to assess and monitor treatment 
   effectiveness
   Taper the withdrawal regimen to account for dosage and any discontinuation 
   symptoms when withdrawing/switching treatment
3. Pharmacologic treatment for all neuropathic pain
                                        (except trigeminal neuralgia)
Offer a choice of amitriptyline, duloxetine, gabapentin, or pregabalin as 
   intial treatment
   If initial treatment is not effective/tolerated, offer 1 of the 3 remaining drugs
   Consider switching again if the 2nd/3rd drugs tried are not effective/tolerated
   Only consider tramadol if acute rescue therapy is needed
   Consider capsaicin cream for people with localized neuropathic pain who
   wish to avoid/cannot tolerate oral treatments
4. Treatments that should not be used
Cannabis sativa extract, capsaicin patch, lacosamide, lamotrigine, 
   levetiracetam, morphine, oxcarbazepine, topiramate, tramadol (for long-term 
   use), venlafaxine
5. Non-pharmacologic treatments in a specialist setting
Spinal cord stimulation (under specific conditions)
Fig. 1 Neuropathic pain pathway adapted from the UKNational Institute
for Health and Care Excellence [106]
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is a possible solution–a simple, cost-effective means of spe-
cialists assessing patients in remote locations. A 3D digital
optical system is a reliable way of examining diabetic foot
ulcers from remote settings, allowing accurate measurements
of the wound [108].
There are national variations in referral patterns for patients
with DSPN among PCPs. A study in the USA, the UK, and
Germany found that for a patient with emerging distal neurop-
athy, US physicians were most active in terms of questioning,
testing, prescribing, and advice giving. US and UK physicians
were more likely to refer to a podiatrist than German physi-
cians [109]. There is considerable variability in referral pat-
terns for diabetes management among different European
countries [110]. Despite these differences, there was relatively
little difference in treatment regimens.
The treatment decision should be tailored to the individual
patient, taking into consideration comorbidities, side effects,
and drug–drug interactions. Although it is unknown whether
treatment preferences differ among different types of special-
ists, a recent survey found that nearly half of patients with
DSPN received nonsteroidal anti-inflammatory drugs
(NSAIDs), in spite of their lack of efficacy, and 43 % required
opioids, whereas only 27 % were prescribed anticonvulsants
and 18 % SNRIs [3]. A large proportion of patients with
DSPN appears to be inappropriately treated with NSAIDs,
and is over-prescribed opioids. Better education is needed
for providers on the treatment of DSPN [111].
Once an ulcer is identified, treatment strategies should shift
from symptomatic therapies to more aggressive interventions.
Although grade 1 ulcerations (superficial ulcerations) may be
managed by a PCP by pressure relief with special footwear,
bracing, or casting, grade 2 ulcerations (ulcers penetrating to
tendon or capsule) or grade 3 ulcerations (ulcers penetrating to
bone or joint) should be referred to a specialist, such as an
orthopedic surgeon or podiatrist, for surgical treatment includ-
ing debridement and possible amputation [112].
Diabetes Education
Lack of patient education – often due to the limited time dur-
ing office visits – is a large barrier to active patient participa-
tion in glycemic control. Although PCPs are the primary dia-
betes educators in their practice, specialists appear to rely
more on certified diabetes educators (CDEs). However, the
proportion of established patients counseled by a CDE at least
once yearly appears to be low [107].
Multidisciplinary Approach
Multidisciplinary teams (Fig. 2) may be the key to reinforcing
patient education, particularly when limited time is a hurdle in
the outpatient clinic. With smaller practices merging into larg-
er group practices, the role of the multidisciplinary team is
growing. In a study of patients with pDPN in a multidisciplin-
ary outpatient setting [113], a PCP referred to a diabetologist-
supervised nurse practitioner who then diagnosed and treated





















































Fig. 2 Multidisciplinary team approach to the management of diabetic neuropathic pain/distal symmetric polyneuropathy. PCP—primary care physician
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Patients who did not respond to treatment were referred to a
specialized outpatient pain clinic. Improvements were found
in all pain scores, and in levels of pain interference in sleep,
general activity, and mood. The authors concluded that a spe-
cialized outpatient clinic for patients with pDPN is an effective
healthcare service. Enhancing the role of nursing staff within a
practice has also been shown to be particularly helpful [114].
Combining a nurse, patient educator, or both with strict
follow-up leads to improvements in patient care and out-
comes. Nurses can serve as a liaison between patient and
physician, help with patient adherence to treatment and edu-
cation, and assume some responsibilities of the physician if
trained with detailed protocols.
The use of multidisciplinary teams significantly decreased
rates of amputation in a hospital in the UK over an 11-year
period [115]. Ulcer management should include surgeons, po-
diatrists, orthotists, clinic-based community nurses, and dia-
betologists. They should have access to facilities for managing
major wounds, including orthopedic or vascular surgery, and
diagnostic services, such as microbiology and radiology
[116]. As DSPN can be a psychosocial stressor, it is reason-
able to include psychologists, social workers, and occupation-
al therapists in the multidisciplinary team.
This multidisciplinary approach also has an economic im-
pact, and with the advent of the Affordable Care Act in the
USA, economic pressures may further limit patient access to
specialty care. Various solutions have been suggested to ad-
dress these issues including expanded fixed per-member per-
month fees to provide specialty care; compensation models
for services such as email, telephone, and curbside consulta-
tions; increasing the number of salaried employees of hospital
or health systems; and increased peer education [117].
Conclusions
DSPN is the most common form of diabetic neuropathy and a
significant source of patient distress, and an economic and
resource burden. Complications include depression, poor
sleep, foot ulcers, loss of ambulation, loss of overall function,
and amputation. The primary treatment should focus on strict
glycemic control and adjustment of modifiable risk factors.
There are currently no curative therapies, and symptomatic
treatments are recommended by various professional socie-
ties. Barriers to effective management include failure to rec-
ognize DSPN, particularly when it is asymptomatic. Patients
may be in denial of their disease and refuse to actively seek
treatment or become noncompliant with medications and
interventions.
DSPN is managed in several settings by PCPs, specialists,
and nurse practitioners. Management should include patient
education, including foot self-examinations, and lifestyle
modifications, such as smoking cessation, healthy diet, and
exercise. Because strict glycemic control is the mainstay of
DSPN treatment, a PCP, endocrinologist, or diabetologist
should be involved in care. Referral patterns vary widely ac-
cording to geographic location, access to services, provider
preferences, and physician comfort in managing complex as-
pects of the disease. The patient should understand the various
provider roles and who to address with specific questions. The
role of standardized screening tools, the multidisciplinary
team, and models utilizing trained nurse practitioners follow-
ing a neuropathy treatment algorithm are all possible solutions
in the streamlining and improvement of future care. Moving
forward, physicians should make earlier diagnoses and inter-
vene before significant nerve damage occurs.
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